Ocular Therapeutix Inc (OCUL)
Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025
Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market
Entrada Therapeutics to Present at Upcoming Investor Conferences
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
Alkermes plc Reports Third Quarter 2025 Financial Results
Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy
Tenet Reports Strong Third Quarter 2025 Results; Raises 2025 Financial Outlook
RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders
Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025